Lead-time models should not be used to estimate overdiagnosis in cancer screening

Journal of General Internal Medicine

Volumn 29, Issue 9, 2014, Pages 1283-1286

  Zahl, Per Henrik ^a   Jørgensen, Karsten Juhl ^b   Gøtzsche, Peter C ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Rigshospitalet   (Denmark)

Author keywords

cancer; lead time; overdiagnosis; screening

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER OVERDIAGNOSIS; CANCER REGRESSION; CANCER RISK; CANCER SCREENING; FOLLOW UP; HISTORY; HUMAN; LEAD TIME MODEL; MAMMOGRAPHY; PREVALENCE; REVIEW; THEORETICAL MODEL; TIME; EARLY DIAGNOSIS; MORTALITY; PROCEDURES; STANDARDS;

EARLY DETECTION OF CANCER; HUMANS; MODELS, THEORETICAL;

EID: 84906935115     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2812-2     Document Type: Review

References (12)

1. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831-839.
2. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Overestimated lead-time in cancer screening has led to substantial under-estimating of overdiagnosis. Br J Cancer. 2013;109:2014-2019.
3. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6, CD001877. doi: 10.1002/14651858.CD001877.pub5.
4. Zahl P-H, Strand BH, Mæhlen J. Breast cancer incidence in Norway and Sweden during introduction of nation-wide screening: prospective cohort study. BMJ. 2004;328:921-924. (Pubitemid 38496981)
5. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587.
6. Kalager M, Adami H-O, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian Screening program. Ann Intern Med. 2012;156:491-499.
7. Boer R, Warmerdam P, de Koning H, et al. Extra incidence caused by mammographic screening. Lancet. 1994;343:979. (Pubitemid 24117251)
8. Zahl P-H, Mæhlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med. 2008;168:2311-2316.
9. Zahl P-H, Gøtzsche P, Mæhlen J. Natural history of breast cancers detected in the Swedish mammography screening program; a cohort study. Lancet Oncol. 2011;12:1118-1124.
10. Zahl P-H, Mæhlen J. Overdiagnosis of breast cancer after 14 years with mammography screening. Tidsskr Nor Legeforen. 2012;132:414-417.
11. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V, Remington PL. The Wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr. 2006;36:37-47.
12. Andriole GL, Crawford ED, Grubb RL III, et al. Prostate cancer screening in the randomized prostate, lung, colorectal and ovarian cancer screening trial: mortality results after 13 years follow-up. JNCI. 2012;104:125-132.